These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 29989016)

  • 21. Covid-19 Vaccine Surveillance in Saudi Arabia: Opportunities for Real-time Assessment.
    Albogami Y; Alkofide H; Alrwisan A
    Saudi Pharm J; 2021 Aug; 29(8):914-916. PubMed ID: 34305424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacovigilance in oncology: evaluation of current practice and future perspectives.
    Baldo P; De Paoli P
    J Eval Clin Pract; 2014 Oct; 20(5):559-69. PubMed ID: 24909067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Community pharmacists' knowledge and perceptions about adverse drug reactions and barriers towards their reporting in Eastern region, Alahsa, Saudi Arabia.
    Khan TM
    Ther Adv Drug Saf; 2013 Apr; 4(2):45-51. PubMed ID: 25083250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Knowledge and Attitude of Health-Care Professionals Toward Adverse Drug Reactions Reporting at King Saud Medical City.
    Moinuddin K; Ali S; Al-Aqqad AQ; Salem SO; Al-Dossari MA; Ananzeh AM; Baqar JB
    J Pharm Bioallied Sci; 2018; 10(1):29-34. PubMed ID: 29657505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Some observations on pharmacoepidemiology in Europe.
    van Boxtel CJ; Wang G
    Neth J Med; 1997 Dec; 51(6):205-12. PubMed ID: 9499691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding Patient Needs Regarding Adverse Drug Reaction Reporting Smartphone Applications: A Qualitative Insight from Saudi Arabia.
    Kassem LM; Alhabib B; Alzunaydi K; Farooqui M
    Int J Environ Res Public Health; 2021 Apr; 18(8):. PubMed ID: 33917014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A need for One Health approach - lessons learned from outbreaks of Rift Valley fever in Saudi Arabia and Sudan.
    Hassan OA; Ahlm C; Evander M
    Infect Ecol Epidemiol; 2014; 4():. PubMed ID: 24505511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Substance use disorders in Saudi Arabia: a scoping review.
    Saquib N; Rajab AM; Saquib J; AlMazrou A
    Subst Abuse Treat Prev Policy; 2020 Jun; 15(1):41. PubMed ID: 32552804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Perspective of Saudi undergraduate pharmacy students on pharmacovigilance and adverse drug reaction reporting: A National Survey.
    Alkayyal N; Cheema E; Hadi MA
    Curr Pharm Teach Learn; 2017 Sep; 9(5):779-785. PubMed ID: 29233304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring New Zealand prescription data using sequence symmetry analyses for predicting adverse drug reactions.
    Nishtala PS; Chyou TY
    J Clin Pharm Ther; 2017 Apr; 42(2):189-194. PubMed ID: 27957745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse drug reactions in patients older than 70 years during the heat wave occurred in France in summer 2003: A study from the French PharmacoVigilance Database.
    Michenot F; Sommet A; Bagheri H; Lapeyre-Mestre M; Montastruc JL;
    Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):735-40. PubMed ID: 16924603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of the Xuesaitong injection in China: results from a large-scale multicentre post-marketing surveillance study in a real-world setting.
    He Y; Gao XM; Li L; Liu XG; Liu W; Hong XJ; Huang BH; Yang HL; Xue MH; Wu XJ; Liu JF
    Curr Med Res Opin; 2020 Dec; 36(12):1947-1953. PubMed ID: 33016133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
    Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploring healthcare professionals' knowledge, attitude, and practices towards pharmacovigilance: a cross-sectional survey.
    Hussain R; Hassali MA; Hashmi F; Akram T
    J Pharm Policy Pract; 2021 Jan; 14(1):5. PubMed ID: 33397478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse Drug Reaction (ADR) as a Cause of Hospitalization at a Government Hospital in Saudi Arabia: A Prospective Observational Study.
    Alayed N; Alkhalifah B; Alharbi M; Alwohaibi N; Farooqui M
    Curr Drug Saf; 2019; 14(3):192-198. PubMed ID: 31109277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Organization and results of drug vigilance in France].
    Bégaud B; Chaslerie A; Haramburu F
    Rev Epidemiol Sante Publique; 1994; 42(5):416-23. PubMed ID: 7973001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse drug reactions that arise from the use of medicinal products outside the terms of the marketing authorisation.
    Mirosevic Skvrce N; Galic I; Pacadi C; Kandzija N; Mucalo I
    Res Social Adm Pharm; 2020 Jul; 16(7):928-934. PubMed ID: 31630960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Challenges in Post-marketing Studies of Biological Drugs in the Era of Biosimilars: A Report of the International Society for Pharmacoepidemiology 2019 Mid-Year Meeting in Rome, Italy.
    Ingrasciotta Y; Sultana J; Kirchmayer U; Trifirò G
    BioDrugs; 2019 Aug; 33(4):345-352. PubMed ID: 31313085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Defining 'surveillance' in drug safety.
    Aronson JK; Hauben M; Bate A
    Drug Saf; 2012 May; 35(5):347-57. PubMed ID: 22462653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world data in Saudi Arabia: Current situation and challenges for regulatory decision-making.
    Alnofal FA; Alrwisan AA; Alshammari TM
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1303-1306. PubMed ID: 32458499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.